D3 BIO
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs โ where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
D3 BIO
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2014-01-01
Address:
Shangai, Jiangxi, China
Country:
China
Website Url:
http://www.d3bio.com
Status:
Active
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Domain Not Resolving
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Current Employees Featured
Founder
Investors List
Sequoia Capital China
Sequoia Capital China investment in Series A - D3 Bio
Boyu Capital
Boyu Capital investment in Series A - D3 Bio
WuXi AppTec
WuXi AppTec investment in Series A - D3 Bio
Matrix Partners China
Matrix Partners China investment in Series A - D3 Bio
Temasek Holdings
Temasek Holdings investment in Series A - D3 Bio
Official Site Inspections
http://www.d3bio.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "D3 Bio"
D3 Bio - Crunchbase Company Profile & Funding
D3 Bio may be growing as it has recently appointed a new independent board member, which could indicate a strategic move to strengthen its governance โฆSee details»
D3 Bio - LinkedIn
D3 Bio | 399 followers on LinkedIn. Biotechnology company focusing on development and registration of innovative medicines in oncology and immunology.See details»
George Chen โ Co-Founder, Chairman & CEO, D3 Bio
Aug 28, 2024 Iโd like to highlight that D3 Bio is an organization built on agility and efficiency, with a strong commitment to excellence in both discovery and development. This positions us as โฆSee details»
D3 Bio Company Profile - Office Locations, Competitors, Revenue โฆ
D3 Bio $200 m in total funding,. See insights on D3 Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
D3 Bio (Wuxi) Co. Ltd - Drug pipelines, Patents, Clinical trials
Explore D3 Bio (Wuxi) Co. Ltd with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, and 1 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic โฆSee details»
D3 Bio, Inc - Drug pipelines, Patents, Clinical trials - Synapse
Explore D3 Bio, Inc with its drug pipeline, therapeutic area, technology platform, 16 news.See details»
D3 Bio - Org Chart, Teams, Culture & Jobs - The Org
View D3 Bio's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
D3 Bio appoints Dr. Antoine Yver as Independent Board Member
Mar 8, 2024 He currently serves as Chairman of Development at Centessa Pharmaceuticals and as independent director on the board of Sanofi SA. Dr. Yver is also Founder of โThe Blue โฆSee details»
D3 Bio 2025 Company Profile: Valuation, Funding & Investors
D3 Bio General Information Description. Developer of biotechnology focused on the development and innovation of drugs in oncology and immunology. The company focuses on the discovery, โฆSee details»
D3 Bio Announces Oral Presentation of Clinical Data for D3S-001 โฆ
Apr 21, 2025 Shanghai, China โ April 16, 2025 โ D3 Bio, a global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, announced โฆSee details»
D3 Bio (China) Funding: $262M - Medical Startups
Apr 2, 2025 D3 Bio identifies areas of unmet need in immunology and oncology and use existing clinical data to find precision medicine targets and delivery methods with the potential to โฆSee details»
D3 Bio Completes $62 Million Series A+ - Cooley
Shanghai โ April 8, 2024 โ Cooley advised D3 Bio, an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs, on the โฆSee details»
D3 Bio Completes Series A+ Round to Advance Innovative โฆ
Apr 8, 2024 For more information please visit: www.d3bio.com. About Medicxi Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across โฆSee details»
D3 Bio Inc. - BioCentury Company Profiles - BCIQ
Apr 11, 2024 D3 Bio Inc. - BioCentury Company Profiles for the biopharma industrySee details»
D3 Bio - Funding, Financials, Valuation & Investors - Crunchbase
D3 Bio is a biotechnology company focusing on the development and registration of medicines.See details»
D3 Bio - VentureRadar
D3Bio has built a pipeline of multiple pre-clinical stage oncology programs, all of which have first-in-class or best-in-class potential and carry foundational properties targeting immune โฆSee details»
D3 Bio Launches with US$200 Million Investment to Develop ... - BioSpace
Nov 17, 2020 Global biotech headed by seasoned industry veterans secures backing from world-class investor syndicate Novel approach to guided drug development utilizes clinical and โฆSee details»
Medicxi Announces $40m investment in D3 Bio
Apr 8, 2024 Medicxi Announces $40m investment in D3 Bio · Investment will support development of a differentiated pipeline in oncology · Most advanced asset is D3S-001 with โฆSee details»
D3 Bio Launches with $200 Million to Advance Precision Medicine โฆ
On November 17th, global biotech D3 Bio launched with a $200 million Series A financing by Boyu Capital, Matrix Partners China, Wuxi AppTech, Temasek, and Sequoia. The funding will โฆSee details»
่ฟ็คๅๅ ็ซ็ฒพๅๆฒป็่ฏ็ฉ็ ๅๅD3 BioๅฎๆA+่ฝฎ็ณปๅ่ต๏ผๆจ่ฟ่ฟ โฆ
Apr 8, 2024 The substantial investment of US$62M in this round underscores D3 Bio's steadfast commitment to advancing its pioneering oncology pipeline. The funding will be allocated to โฆSee details»